Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

University of Toronto

$137,209.00

Cross-linked polyester-based depot systems for sustained drug delivery: determining the relationship between composition, properties and performance

EF 2017-18

Résumé
There are currently more than 20 pharmaceutical products that include implantable, insertable or injectabledrug delivery systems that are formed from the copolymer poly(lactide-co-glycolide) (PLGA) and providesustained release of drug therapy over time. The sustained drug release that is achieved with a singleadministration, eliminates the need for daily or weekly drug administrations and as a result has a profoundlypositive impact on a patient's quality of life, patient compliance and leads to significant reductions in healthcare costs. These products are currently used to treat critical medical conditions including diabetes,endometriosis, prostate cancer and schizophrenia. While PLGA-based systems have provided a deliverysolution to many drugs, it is clear, a new polymeric delivery system is needed to meet the needs of thepharmaceutical industry. Given that each drug is unique in terms of its physico-chemical properties and thatpolymer-drug interaction and compatibility are key metrics that influence the performance of polymericdelivery formulations there is no single polymer that can serve as a universal material for formulation of alldrugs. For this reason, Pendant Biosciences (a Canadian company) has patented, and in collaboration with theAllen laboratory filed an additional provisional patent application, on a flexible polymer platform that includesrecognized building blocks that produce cross-linked biocompatible systems for prolonged delivery of a widerange of drugs. If successful, the proposed research will result in (1) identification of a lead drug-polymerproduct for development by Pendant Biosciences; (2) a 'tool-box' of biocompatible polymer materials tofacilitate drug-delivery research in academic and industrial settings and (3) increased scientific awareness ofthe physical and chemical metrics responsible for the performance of a drug-polymer combination product.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
508274-2017
Name nom
Allen, Christine
Department département
Pharmacy, Leslie Dan Faculty of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
137209
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
2000
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Materials science and technology
Research subject fr
Science et technologie des matériaux
Partie
1
Nb partie
3
Application title
Cross-linked polyester-based depot systems for sustained drug delivery: determining the relationship between composition, properties and performance
Keyword
NSERC
Application summary
There are currently more than 20 pharmaceutical products that include implantable, insertable or injectabledrug delivery systems that are formed from the copolymer poly(lactide-co-glycolide) (PLGA) and providesustained release of drug therapy over time. The sustained drug release that is achieved with a singleadministration, eliminates the need for daily or weekly drug administrations and as a result has a profoundlypositive impact on a patient's quality of life, patient compliance and leads to significant reductions in healthcare costs. These products are currently used to treat critical medical conditions including diabetes,endometriosis, prostate cancer and schizophrenia. While PLGA-based systems have provided a deliverysolution to many drugs, it is clear, a new polymeric delivery system is needed to meet the needs of thepharmaceutical industry. Given that each drug is unique in terms of its physico-chemical properties and thatpolymer-drug interaction and compatibility are key metrics that influence the performance of polymericdelivery formulations there is no single polymer that can serve as a universal material for formulation of alldrugs. For this reason, Pendant Biosciences (a Canadian company) has patented, and in collaboration with theAllen laboratory filed an additional provisional patent application, on a flexible polymer platform that includesrecognized building blocks that produce cross-linked biocompatible systems for prolonged delivery of a widerange of drugs. If successful, the proposed research will result in (1) identification of a lead drug-polymerproduct for development by Pendant Biosciences; (2) a 'tool-box' of biocompatible polymer materials tofacilitate drug-delivery research in academic and industrial settings and (3) increased scientific awareness ofthe physical and chemical metrics responsible for the performance of a drug-polymer combination product.